Schering-Plough CEO applauded for turnaround

BusinessWeek adds to the praise that's been heaped around Schering-Plough CEO Fred Hassan. After giving shareholders a dose of realism in 2003 when he took over, Hassan has been steadily rebuilding the company and positioning it for the future. Through it all he's had to inspire demoralized workers as well as investors, and has been given a tremendous amount of credit for accomplishing the task. His new mission lies in inspiring the workers at Organon Biosciences, which is being acquired in a $14.6 billion takeover. Hassan gave himself seven years to complete the turnaround, but some analysts say he's done a fine job in less than that.

- read the article from BusinessWeek

ALSO: Schering-Plough's stock was up this morning on more praise from analysts while the FTC is asking for more information on the takeover. Company officials describe the request as routine. Report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.